Brokerages Set Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) PT at $11.00

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) has received an average rating of "Buy" from the thirteen research firms that are covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $11.75.

A number of equities research analysts have weighed in on the stock. Leerink Partners raised shares of Amylyx Pharmaceuticals from a "market perform" rating to an "outperform" rating and boosted their target price for the stock from $4.00 to $10.00 in a report on Wednesday, May 7th. Leerink Partnrs raised shares of Amylyx Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, May 6th. Guggenheim assumed coverage on shares of Amylyx Pharmaceuticals in a research note on Tuesday, June 24th. They issued a "buy" rating and a $17.00 price objective on the stock. Wall Street Zen lowered shares of Amylyx Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Saturday, June 14th. Finally, Jefferies Financial Group assumed coverage on shares of Amylyx Pharmaceuticals in a research note on Tuesday, June 24th. They issued a "hold" rating on the stock.

Amylyx Pharmaceuticals Trading Up 3.9%

AMLX traded up $0.29 during trading on Wednesday, reaching $7.68. 1,682,665 shares of the company's stock were exchanged, compared to its average volume of 1,152,166. Amylyx Pharmaceuticals has a one year low of $1.76 and a one year high of $7.73. The firm has a fifty day moving average price of $5.53 and a two-hundred day moving average price of $4.36.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.42) earnings per share for the quarter, topping analysts' consensus estimates of ($0.45) by $0.03. As a group, research analysts predict that Amylyx Pharmaceuticals will post -2.2 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of AMLX. Valeo Financial Advisors LLC bought a new position in Amylyx Pharmaceuticals during the first quarter worth $35,000. Alpine Global Management LLC bought a new position in Amylyx Pharmaceuticals during the fourth quarter worth $45,000. Fox Run Management L.L.C. bought a new position in Amylyx Pharmaceuticals during the fourth quarter worth $45,000. R Squared Ltd boosted its stake in Amylyx Pharmaceuticals by 99.9% during the first quarter. R Squared Ltd now owns 12,736 shares of the company's stock worth $45,000 after acquiring an additional 6,366 shares in the last quarter. Finally, RPO LLC bought a new position in Amylyx Pharmaceuticals during the fourth quarter worth $46,000. 95.84% of the stock is owned by institutional investors.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.